September 28, 2014 – New breast cancer treatment has appeared on the market with good results as never before, experts say.
A new drug against metastatic breast cancer called Perjeta (Pertuzumab), from the Roche Company,seems to prolong life in women with advanced breast cancer, a new study has revealed. The expertsof this study encourage its utilization to help women around the world in their fight against the disease. Designed specifically to target and treat metastatic breast cancer, Perjeta follows Herceptin,with which it can be combined with and associated with chemotherapy.
Perjeta, which was approved by the FDA authorities after it was tested in the Roche-backed study of over 800 women with cancer of the breast, is now considered as one of the best breast cancer drug on the market.
According to researchers, women who were diagnosed with breast cancer HER2 positive who receivedPerjeta in addition of the drug Herceptin (trastuzumab) and chemotherapy lived more than 15months longer than those who were treated with Herceptin and chemotherapy alone. This is important news because HER2 positive represents about a quarter of all breast cancers. Both Perjetaand Herceptin are antibodies designed to block the function of HER2, a protein produced by a cancer-related gene.
We have never recorded such an extension of life in any drug study in metastatic breast cancer before, the experts say. The medication has the property to stop the disease from spreading to other parts of the body over a long period of time. The result confirms the importance of combiningmedications to better fight tumor cells in a variety of ways. Many experts say they are delighted andconsider Perjeta as a ‘unique treatment.”
This new treatment is produced by the Roche pharmaceutical company; it helps fighting against an aggressive form of breast cancer. Perjeta, also called Pertuzumab is a drug designed for women withmetastatic, HER2-positive breast cancer, and have not yet received any treatment in combination with Herceptin or docetaxel before, said the specialists of Roche, the Swiss pharmaceutical company, in a statement. This new breast cancer drug has provided hope for women HER2-positive breast as never before.
Among the most daunting forms of cancer, HER2-positive is one of the top, which is distinguished byits aggressiveness. HER2 (Human Epidermal Growth Factor Receptor 2) is a receptor normally presents on the membrane of many cells, and regulates growth and proliferation. When the number of HER2 increases abnormally, it then leads to uncontrolled cell growth which may be malignant. Approximately 20-25% of breast cancers are HER2-positive and have a faster progression characteristic. Most women with this form of breast cancer are between 30 and 45 years. They have negative response to drug treatment, and in general, a negative prognosis.
IncreaseSurvival Among Breast Cancer Patients
The pharmaceutical group Roche had already put on the market about a decade ago a new specific treatment for this form of breast cancer, Herceptin, which has enabled, in conjunction with chemotherapy , to extend the duration of a few months of life for many patients with advanced formsof advanced breast cancer. But this new cancer treatment will also permit more healing for patientsin early stages of this form of the disease.
Today, the pharmaceutical company has a new compound in the fight against breast cancer, Perjeta (Pertuzumab), which has very promising medical properties, reported the group. The Swiss companysaid that patients treated with combined therapy Perjeta to live about 15.5 months longer, comparedto patients treated with Herceptin alone, even if it is in combination with chemotherapy. The association with Perjeta reduces risk of death significantly.
This new breast cancer treatment is the most important progress in the treatment of aggressiveforms breast malignancies, since the marketing of Herceptin. Today, the future of breast cancer treatment and the possibility of survival is more than a promise, it becomes a reality, they experts say.